



16th September 2025

Block Trade

SomnoMed Limited (SomnoMed or the Company) (ASX: SOM) Somnomed advises that a block trade of 16,071,430 shares at a price of \$0.70 per share was successfully completed today on the ASX. The transaction was comprised as follows:

- 2,860,000 shares (representing 1.3% of shares on issue) from the SomnoMed employee share trust. These shares are residual issued shares within a legacy structure.
- 13,211,430 shares (representing 6.1% of shares on issue) from TDM Growth Partners. The sale results in TDM's relevant interest in SomnoMed reducing from 31.3% to 25.0%. Consistent with market practice, TDM has agreed to a restriction on selling further shares for a period ending after the announcement of interim results in February 2026.

In supporting this transaction, the Company and TDM were aligned in the goal of diversifying Somnomed's share register and improving free float and liquidity through a structure that provided investor access without diluting existing shareholders. To that end, the Company is delighted with participation from numerous new and existing high quality institutional shareholders as well as additional retail shareholders.

Authorised by the Company Secretary of SomnoMed Limited

About SomnoMed SomnoMed is a public company providing treatment solutions for sleep-related breathing disorders including obstructive sleep apnea, snoring and bruxism. SomnoMed was commercialised on the basis of extensive clinical research. Supporting independent clinical research, continuous innovation and instituting medical manufacturing standards has resulted in SomnoDent[®] becoming the state-of-the-art and clinically proven medical oral appliance therapy for more than 1 million patients in over 20 countries. For additional information, visit SomnoMed at <http://www.somnomed.com.au>

Investor Enquiries
Investor Relations
ir@somnomed.com

For personal use only